Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Wayne Border

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Disorders

Anatomy

Physiology

Gene Expression

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
57
Noble, Nancy
10
Huang, Yufeng
6
Yu, Ling
5
Peters, H
5
Kagami, Shoji
4
Gaedeke, Jens
3
Lawrence, Daniel
3
Zhang, jiandong
2
Shihab, Fuad
2
Westenfelder, Christof
1
Tanner, AM
1
Tsujie, M
1
Sporn, Michael B.
1
Hori, Masatsugu
1
Imai, Enyu

Sign-in to see all Coauthors

Publications

TOP 3
Huang Yufeng; Border Wayne A; Lawrence Daniel A; Noble Nancy A
Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.
Zhang Jiandong; Noble Nancy A; Border Wayne A; Owens Rick T; Huang Yufeng
Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.
Huang Wei; Xu Chen; Kahng Kyoung W; Noble Nancy A; Border Wayne A; Huang Yufeng
Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Wayne Border (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Huang Yufeng; Border Wayne A; Lawrence Daniel A; Noble Nancy A
Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.
American journal of physiology. Renal physiology 2009;297(4):F1045-54.
2008: Zhang Jiandong; Noble Nancy A; Border Wayne A; Owens Rick T; Huang Yufeng
Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.
American journal of physiology. Endocrinology and metabolism 2008;295(4):E810-9.
2008: Huang Wei; Xu Chen; Kahng Kyoung W; Noble Nancy A; Border Wayne A; Huang Yufeng
Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.
American journal of physiology. Renal physiology 2008;294(6):F1287-95.
2008: Huang Yufeng; Border Wayne A; Yu Ling; Zhang Jiandong; Lawrence Daniel A; Noble Nancy A
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 2008;19(2):329-38.
2007: Huang Y; Noble N A; Zhang J; Xu C; Border W A
Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells.
Kidney international 2007;72(1):45-52.
2007: Huang Yufeng; Border Wayne A; Noble Nancy A
Functional renin receptors in renal mesangial cells.
Current hypertension reports 2007;9(2):133-9.
2006: Huang Y; Border W A; Lawrence D A; Noble N A
Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.
Kidney international 2006;70(3):515-22.
2006: Huang Y; Border W A; Noble N A
Perspectives on blockade of TGFbeta overexpression.
Kidney international 2006;69(10):1713-4.
2006: Huang Y; Wongamorntham S; Kasting J; McQuillan D; Owens R T; Yu L; Noble N A; Border W
Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.
Kidney international 2006;69(1):105-13.
2005: Gaedeke Jens; Noble Nancy A; Border Wayne A
Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1.
Kidney international 2005;68(5):2042-9.
2004: Yu Ling; Border Wayne A; Anderson Ian; McCourt Matthew; Huang Yufeng; Noble Nancy A
Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.
Kidney international 2004;66(5):1774-84.
2004: Gaedeke Jens; Noble Nancy A; Border Wayne A
Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells.
Kidney international 2004;66(1):112-20.
2003: Aben Joris A; Hoogervorst Dennis A; Paul Leendert C; Borrias Maria C; Noble Nancy A; Border Wayne A; Bruijn Jan A; de Heer Emile
Genes expressed by the kidney, but not by bone marrow-derived cells, underlie the genetic predisposition to progressive glomerulosclerosis after mesangial injury.
Journal of the American Society of Nephrology : JASN 2003;14(9):2264-70.
2003: Yu Ling; Border Wayne A; Huang Yufeng; Noble Nancy A
TGF-beta isoforms in renal fibrogenesis.
Kidney international 2003;64(3):844-56.
2003: Huang Yufeng; Haraguchi Masashi; Lawrence Daniel A; Border Wayne A; Yu Ling; Noble Nancy A
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
The Journal of clinical investigation 2003;112(3):379-88.
2003: Peters Harm; Border Wayne A; Rückert Matthias; Krämer Stephanie; Neumayer Hans-H; Noble Nancy A
L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis.
Kidney international 2003;63(4):1382-92.
2002: Gaedeke Jens; Noble Nancy A; Border Wayne A
Angiotensin II and progressive renal insufficiency.
Current hypertension reports 2002;4(5):403-7.
2002: Yu Ling; Noble Nancy A; Border Wayne A
Therapeutic strategies to halt renal fibrosis.
Current opinion in pharmacology 2002;2(2):177-81.
2001: Border W A; Noble N
Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases.
Seminars in nephrology 2001;21(6):563-72.
2001: Haraguchi M; Border W A; Huang Y; Noble N A
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.
Kidney international 2001;59(6):2146-55.
2001: Gaedeke J; Peters H; Noble N A; Border W A
Angiotensin II, TGF-beta and renal fibrosis.
Contributions to nephrology 2001;(135):153-60.
2000: Peters H; Border W A; Noble N A
Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis.
Kidney international 2000;57(4):1493-501.
2000: Border W A; Noble N A
Effect of maximal reduction of angiotensin in renal fibrosis: bad news-good news from a pediatric mouse.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2000;35(4):773-6.
2000: Peters H; Border W A; Noble N A
Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis.
Kidney international 2000;57(3):992-1001.
1999: Peters H; Border W A; Noble N A
From rats to man: a perspective on dietary L-arginine supplementation in human renal disease.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14(7):1640-50.
1999: Peters H; Border W A; Noble N A
L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis.
Kidney international 1999;55(6):2264-73.
1999: Yamamoto T; Noble N A; Miller D E; Gold L I; Hishida A; Nagase M; Cohen A H; Border W A
Increased levels of transforming growth factor-beta in HIV-associated nephropathy.
Kidney international 1999;55(2):579-92.
1999: Isaka Y; Akagi Y; Ando Y; Tsujie M; Sudo T; Ohno N; Border W A; Noble N A; Kaneda Y; Hori M; Imai E
Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis.
Kidney international 1999;55(2):465-75.
1999: Peters H; Border W A; Noble N A
Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14 Suppl 4():22-3.
1998: Peters H; Border W A; Noble N A
Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade.
Kidney international 1998;54(5):1570-80.
1998: Border W A; Noble N A
Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy.
Kidney international 1998;54(4):1390-1.
1998: Border W A; Noble N A
Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis.
Hypertension 1998;31(1 Pt 2):181-8.
1997: Noble N A; Border W A
Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?
Seminars in nephrology 1997;17(5):455-66.
1997: Peters H; Noble N A; Border W A
Transforming growth factor-beta in human glomerular injury.
Current opinion in nephrology and hypertension 1997;6(4):389-93.
1997: Border W A; Noble N A
TGF-beta in kidney fibrosis: a target for gene therapy.
Kidney international 1997;51(5):1388-96.
1997: Kagami S; Kuhara T; Okada K; Kuroda Y; Border W A; Noble N A
Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells.
Kidney international 1997;51(3):664-71.
1996: Ketteler M; Ikegaya N; Brees D K; Border W A; Noble N A
L-arginine metabolism in immune-mediated glomerulonephritis in the rat.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1996;28(6):878-87.
1996: Shihab F S; Andoh T F; Tanner A M; Noble N A; Border W A; Franceschini N; Bennett W M
Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.
Kidney international 1996;49(4):1141-51.
1996: Isaka Y; Brees D K; Ikegaya K; Kaneda Y; Imai E; Noble N A; Border W A
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney.
Nature medicine 1996;2(4):418-23.
1996: Yamamoto T; Noble N A; Cohen A H; Nast C C; Hishida A; Gold L I; Border W A
Expression of transforming growth factor-beta isoforms in human glomerular diseases.
Kidney international 1996;49(2):461-9.
1995: Border W A; Noble N A
Targeting TGF-beta for treatment of disease.
Nature medicine 1995;1(10):1000-1.
1995: Shihab F S; Yamamoto T; Nast C C; Cohen A H; Noble N A; Gold L I; Border W A
Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts.
Journal of the American Society of Nephrology : JASN 1995;6(2):286-94.
1995: Border W A; Noble N A; Ketteler M
TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention.
Kidney international. Supplement 1995;49():S59-61.
1995: Narita I; Border W A; Ketteler M; Ruoslahti E; Noble N A
L-arginine may mediate the therapeutic effects of low protein diets.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(10):4552-6.
1995: Narita I; Border W A; Ketteler M; Noble N A
Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis.
Laboratory investigation; a journal of technical methods and pathology 1995;72(1):17-24.
1995: Ketteler M; Noble N A; Border W A
Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?
Annual review of physiology 1995;57():279-95.
1994: Ketteler M; Noble N A; Border W A
Increased expression of transforming growth factor-beta in renal disease.
Current opinion in nephrology and hypertension 1994;3(4):446-52.
1994: Kagami S; Border W A; Miller D E; Noble N A
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.
The Journal of clinical investigation 1994;93(6):2431-7.
1994: Yamamoto T; Noble N A; Miller D E; Border W A
Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis.
Kidney international 1994;45(3):916-27.
1994: Ruoslahti E; Noble N A; Kagami S; Border W A
Integrins.
Kidney international. Supplement 1994;44():S17-22.
1994: Border W A
Transforming growth factor-beta and the pathogenesis of glomerular diseases.
Current opinion in nephrology and hypertension 1994;3(1):54-8.
1994: Border W A; Brees D; Noble N A
Transforming growth factor-beta and extracellular matrix deposition in the kidney.
Contributions to nephrology 1994;107():140-5.
1993: Kagami S; Border W A; Ruoslahti E; Noble N A
Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis.
Laboratory investigation; a journal of technical methods and pathology 1993;69(1):68-76.
1993: Border W A; Noble N A
Cytokines in kidney disease: the role of transforming growth factor-beta.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;22(1):105-13.
1993: Yamamoto T; Nakamura T; Noble N A; Ruoslahti E; Border W A
Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(5):1814-8.
1992: Tomooka S; Border W A; Marshall B C; Noble N A
Glomerular matrix accumulation is linked to inhibition of the plasmin protease system.
Kidney international 1992;42(6):1462-9.
1992: Miller D E; Noble N A; Yu X; Border W A
Molecular and cellular biological techniques in the study of glomerular diseases.
Seminars in nephrology 1992;12(6):506-15.
1992: Border W A; Noble N A; Yamamoto T; Harper J R; Yamaguchi Y u; Pierschbacher M D; Ruoslahti E
Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease.
Nature 1992;360(6402):361-4.
1992: Border W A; Ruoslahti E
Transforming growth factor-beta in disease: the dark side of tissue repair.
The Journal of clinical investigation 1992;90(1):1-7.
1992: Nakamura T; Miller D; Ruoslahti E; Border W A
Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1.
Kidney international 1992;41(5):1213-21.
1992: Border W A; Noble N A; Yamamoto T; Tomooka S; Kagami S
Antagonists of transforming growth factor-beta: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis.
Kidney international 1992;41(3):566-70.
1992: Noble N A; Harper J R; Border W A
In vivo interactions of TGF-beta and extracellular matrix.
Progress in growth factor research 1992;4(4):369-82.
1991: Okuda S; Nakamura T; Yamamoto T; Ruoslahti E; Border W A
Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(21):9765-9.
1991: Border W A; Okuda S; Nakamura T; Languino L R; Ruoslahti E
Role of TGF-beta 1 in experimental glomerulonephritis.
Ciba Foundation symposium 1991;157():178-89; discussion 189-93.
1990: Border W A; Ruoslahti E
Transforming growth factor-beta 1 induces extracellular matrix formation in glomerulonephritis.
Cell differentiation and development : the official journal of the International Society of Developmental Biologists 1990;32(3):425-31.
1990: Okuda S; Languino L R; Ruoslahti E; Border W A
Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix.
The Journal of clinical investigation 1990;86(2):453-62.
1990: Border W A; Okuda S; Languino L R; Sporn M B; Ruoslahti E
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1.
Nature 1990;346(6282):371-4.
1990: Marinides G N; Groggel G C; Cohen A H; Border W A
Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy.
Kidney international 1990;37(2):749-57.
1990: Border W A; Okuda S; Languino L R; Ruoslahti E
Transforming growth factor-beta regulates production of proteoglycans by mesangial cells.
Kidney international 1990;37(2):689-95.
1989: Border W A; Okuda S; Nakamura T
Extracellular matrix and glomerular disease.
Seminars in nephrology 1989;9(4):307-17.
1988: Border W A
Distinguishing minimal-change disease from mesangial disorders.
Kidney international 1988;34(3):419-34.
1988: Groggel G C; Stevenson J; Hovingh P; Linker A; Border W A
Changes in heparan sulfate correlate with increased glomerular permeability.
Kidney international 1988;33(2):517-23.
1987: Marinides G N; Groggel G C; Cohen A H; Cook T; Baranowski R L; Westenfelder C; Border W A
Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.
The American journal of pathology 1987;129(2):394-401.
1987: Groggel G C; Hovingh P; Border W A; Linker A
Changes in glomerular heparan sulfate in puromycin aminonucleoside nephrosis.
The American journal of pathology 1987;128(3):521-7.
1987: Groggel G C; Border W A; Westenfelder C
The kidney in hypergammaglobulinemic purpura.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1987;9(2):172-5.

Sign-in to see more